Clinical Trials Logo

IDH2 Gene Mutation clinical trials

View clinical trials related to IDH2 Gene Mutation.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03881735 Withdrawn - Clinical trials for Refractory Acute Myeloid Leukemia

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Start date: December 2, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well enasidenib works in treating in patients with acute myeloid leukemia with an IDH2 gene mutation that has come back or has not responded to treatment. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. In this study we are investing if enasidenib can be used as maintenance therapy post salvage induction chemotherapy.